Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1 Renal Pelvis and Ureter Urothelial Carcinoma 1 Recurrence 1 Disease 1 Carcinoma, Transitional Cell 1

Interventions

Cyclophosphamide 23 venetoclax 17 Dexamethasone 16 pembrolizumab 15 fludarabine 15 Cytarabine 13 pomalidomide 8 Rituximab 8 Gemcitabine 8 Carboplatin 8 Azacitidine 8 glofitamab 7 fludarabine phosphate 7 Lenalidomide 7 selinexor 6 Paclitaxel 6 Injections 6 Immunotherapy, Adoptive 6 Granulocyte Colony-Stimulating Factor 6 Cisplatin 6 daratumumab 5 Temozolomide 5 Bevacizumab 5 zanubrutinib 4 ruxolitinib 4 Surgical Procedures, Operative 4 Oxaliplatin 4 Nivolumab 4 Drug Therapy 4 Decitabine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Recurrence × Nephroureterectomy × Clear all

NCT06169436 2023-12-13

Translational Cancer Observational Protocol

IRCCS San Raffaele

Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡